CN108578553A - A kind of animal compound synergy cefquinome sulfate injection and preparation method - Google Patents
A kind of animal compound synergy cefquinome sulfate injection and preparation method Download PDFInfo
- Publication number
- CN108578553A CN108578553A CN201810560815.3A CN201810560815A CN108578553A CN 108578553 A CN108578553 A CN 108578553A CN 201810560815 A CN201810560815 A CN 201810560815A CN 108578553 A CN108578553 A CN 108578553A
- Authority
- CN
- China
- Prior art keywords
- cefquinome sulfate
- animal compound
- compound synergy
- dispersant
- cefquinome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of animal compound synergy cefquinome sulfate injection, active ingredient includes garlic oil, Cefquinome sulfate.The present invention can be obviously improved the therapeutic effect of the mammals of disease of digestive tracts such as transmissible gastroenteritis class, aerogenesis folder film clostridial disease.
Description
Technical field
The present invention relates to livestock-raising medication fields, and in particular to a kind of animal compound synergy cefquinome sulfate injection
And preparation method.
Background technology
With the development of China's livestock breeding industry, the scale expanded of cultivation, the type and quantity of cultivation are continuously obtained
Increase, but during flourishing along with aquaculture, occurs various Animal diseases accordingly, increase and draw
Send out the possibility of animal epidemics.Especially disease caused by virus and bacteria class is relatively conventional on veterinary clinic.Most of illness are dynamic
The cause of disease of object is caused by gram-positive bacteria and/or negative microbial infections.
Cefquinome sulfate has stronger antibacterial activity, and has a broad antifungal spectrum, toxic side effect are small.Cefquinome sulfate is generation
The upper first forth generation animal specific cephalosporin in boundary, is mainly used for pig, ox respiratory disease, vaginitis, endometritis
Etc. a variety of diseases, and preferable therapeutic effect is achieved.But Cefquinome sulfate presss from both sides film for transmissible gastroenteritis class, aerogenesis
The treatment of the disease of digestive tracts such as clostridial disease is but without preferable therapeutic effect.
Invention content
The purpose of the present invention is to provide a kind of animal compound synergy cefquinome sulfate injection, which can show
Write the therapeutic effect for improving Cefquinome sulfate to mammalian digestive tract disease.
The present invention is achieved through the following technical solutions：
A kind of animal compound synergy cefquinome sulfate injection, active ingredient include garlic oil, Cefquinome sulfate.
Active ingredient is garlic oil, Cefquinome sulfate, vitamin E, Radix Codonopsis extract.
Cefquinome sulfate 3%w/v, garlic oil 1%w/v, vitamin E 0.3%w/v, 4%~6%w/ of Radix Codonopsis extract
v。
Further include pharmaceutically acceptable auxiliary material, auxiliary material includes suspending agent, solubilizer, antioxidant, dispersant, wherein
Dispersant includes at least one oils dispersant and at least one esters dispersant.
It is Cefquinome sulfate 3%w/v, garlic oil 1%w/v, vitamin E 0.3%w/v, Radix Codonopsis extract 6%w/v, hard
Resin acid aluminium 2%w/v, sorbester p17 0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, medium chain triglyceride acid esters 30%w/v, note
It penetrates and uses soybean oil 80%w/v.
Cefquinome sulfate 3%w/v, garlic oil 3%w/v, vitamin E 0.3%w/v, Radix Codonopsis extract 5%w/v, tristearin
Sour aluminium 2%w/v, sorbester p17 0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, medium chain triglyceride acid esters 30%w/v, injection
With soybean oil 80%w/v.
It is Cefquinome sulfate 3%w/v, garlic oil 5%w/v, vitamin E 0.3%w/v, Radix Codonopsis extract 4%w/v, hard
Resin acid aluminium 2%w/v, sorbester p17 0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, nutmeg isopropyl ester 40%w/v, note
It penetrates and uses soybean oil 50%w/v.
A kind of preparation method of animal compound synergy cefquinome sulfate injection, includes the following steps：
(1), dissolving suspending agent is reheated after keeping the temperature oils dispersant agitating and heating after 40~60 DEG C of cooling, is cooled to
80 DEG C of addition antioxidants；
(2), continue to cool down, homogenization is spare after Cefquinome sulfate, solubilizer is added；
(3), it after stirring evenly esters dispersant, Radix Codonopsis extract, garlic oil, vitamin E, is added to sulfuric acid cephalo quinoline
Oxime, solubilizer homogeneous mixture in be uniformly mixed to obtain the final product.
Garlic oil has the function of antibacterial anti-inflammatory, anti-platelet aggregation, reducing blood lipid, prevention of arterial atherosis, anti-oxidant etc..
The present invention is to be used cooperatively garlic oil and Cefquinome sulfate, can effectively improve Cefquinome sulfate to suffering from
The therapeutic effect of the mammals of disease of digestive tracts such as transmissible gastroenteritis class, aerogenesis folder film clostridial disease.Certain present invention can also
Enough it is obviously improved the therapeutic effect to disease of digestive tract caused by Escherichia coli.
In a preferred embodiment, the present invention is using garlic oil, Cefquinome sulfate, vitamin E, Radix Codonopsis extract
Cooperation, can be obviously improved the therapeutic effect to disease of digestive tract.
Compared with prior art, the present invention having the following advantages and advantages：
The present invention can be obviously improved the mammal of the disease of digestive tracts such as transmissible gastroenteritis class, aerogenesis folder film clostridial disease
Therapeutic effect.
Specific implementation mode
To make the objectives, technical solutions, and advantages of the present invention clearer, with reference to embodiment, the present invention is made
Further to be described in detail, exemplary embodiment of the invention and its explanation are only used for explaining the present invention, are not intended as to this
The restriction of invention.
Embodiment 1
A kind of animal compound synergy cefquinome sulfate injection is Cefquinome sulfate 3%w/v, garlic oil 1%w/v, hard
Resin acid aluminium 2%w/v, sorbester p17 0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, medium chain triglyceride acid esters 30%w/v, note
It penetrates and uses soybean oil 80%w/v.
Embodiment 2
It is similar with embodiment 1, Cefquinome sulfate 3%w/v, garlic oil 3%w/v, aluminum stearate 2%w/v, sorbester p17
0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, medium chain triglyceride acid esters 30%w/v, injection soybean oil 80%w/v.
Embodiment 3
It is similar with embodiment 1, Cefquinome sulfate 3%w/v, garlic oil 5%w/v, aluminum stearate 2%w/v, sapn
800.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, nutmeg isopropyl ester 40%w/v, injection soybean oil 50%w/v.
Embodiment 4
Similar with embodiment 1, Cefquinome sulfate 3%w/v, garlic oil 1%w/v, vitamin E 0.3%w/v, Radix Codonopsis carry
Take object 6%w/v, aluminum stearate 2%w/v, sorbester p17 0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, medium chain triglyceride
Acid esters 30%w/v, injection soybean oil 80%w/v.
Embodiment 5
Cefquinome sulfate 3%w/v, garlic oil 3%w/v, vitamin E 0.3%w/v, Radix Codonopsis extract 5%w/v, tristearin
Sour aluminium 2%w/v, sorbester p17 0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, medium chain triglyceride acid esters 30%w/v, injection
With soybean oil 80%w/v.
Embodiment 6
It is Cefquinome sulfate 3%w/v, garlic oil 5%w/v, vitamin E 0.3%w/v, Radix Codonopsis extract 4%w/v, hard
Resin acid aluminium 2%w/v, sorbester p17 0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, nutmeg isopropyl ester 40%w/v, note
It penetrates and uses soybean oil 50%w/v.
Blank group 1
Cefquinome sulfate 4%w/v, aluminum stearate 2%w/v, sorbester p17 0.5%w/v, BHA 0.1%w/v, BHT
0.2%w/v, medium chain triglyceride acid esters 30%w/v, injection soybean oil 80%w/v.
Blank group 2
Garlic oil 4%w/v, aluminum stearate 2%w/v, sorbester p17 0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/
V, medium chain triglyceride acid esters 30%w/v, injection soybean oil 80%w/v.
It is above-mentioned to be all made of following preparation method preparation：
Preparation method：
1, injection soybean oil is added in Agitation Tank, 120 DEG C are heated under stirring, keeps the temperature 30 minutes.Then 30% is taken
Soybean oil, be cooled to 60~80 DEG C, dissolve by heating aluminum stearate, Agitation Tank is added.When being cooled to 80 DEG C, BHT, BHA is added,
Continue to cool down after dissolving.After being cooled to room temperature, Cefquinome sulfate, sorbester p17 is added, opens high-shear homogenizing machine, waits for that material is thin
After greasy, high pressure homogenizer, homogeneous to diameter of particle qualification are opened.
2, medium chain triglyceride acid esters, garlic oil, (VE, Radix Codonopsis extract) stir evenly, and Agitation Tank is added and is uniformly mixed to obtain the final product.
For the advantageous effect further illustrated the present invention, the present invention has carried out treatment contrast test.Infectiousness stomach will be suffered from
80 nursings for carrying out same dose, same time of piglet of enteritis class disease, are divided into administration group 1 (applying embodiment 1), administration group
2 (applying embodiment 2), administration group 3 (applying embodiment 3), administration group 4 (applying embodiment 4), administration group 5 (apply embodiment
5), administration group 6 (applying embodiment 6), administration group 7 (applying blank group 1), administration group 8 (applying blank group 2), every group 10, often
Kg weight 2mg intramuscular injection, once every three days.Therapeutic effect is as shown in table 1.
Therapeutic effect of the table 1 to transmissible gastroenteritis class disease
| Cure rate % | |
| Embodiment 1 | 70 |
| Embodiment 2 | 70 |
| Embodiment 3 | 70 |
| Embodiment 4 | 80 |
| Embodiment 5 | 80 |
| Embodiment 6 | 80 |
| Blank group 1 | 30 |
| Blank group 2 | 10 |
As can be seen from the above table, single there was only therapeutic effect and bad, Zhi Nengqi of the Cefquinome sulfate to disease of digestive tract
To certain effect, and cure rate can be significantly improved after being used in combination with garlic oil, and when increase vitamin E and
Therapeutic effect is better after giving up extract.
Above-described specific implementation mode has carried out further the purpose of the present invention, technical solution and advantageous effect
It is described in detail, it should be understood that the foregoing is merely the specific implementation mode of the present invention, is not intended to limit the present invention
Protection domain, all within the spirits and principles of the present invention, any modification, equivalent substitution, improvement and etc. done should all include
Within protection scope of the present invention.
Claims (8)
1. a kind of animal compound synergy cefquinome sulfate injection, which is characterized in that its active ingredient includes garlic oil, sulfuric acid
Cefquinome.
2. animal compound synergy cefquinome sulfate injection as described in claim 1, which is characterized in that active ingredient is big
Garlic oil, Cefquinome sulfate, vitamin E, Radix Codonopsis extract.
3. animal compound synergy cefquinome sulfate injection according to claim 2, which is characterized in that sulfuric acid cephalo quinoline
Oxime 3%w/v, 1~5%w/v of garlic oil, vitamin E 0.3%w/v, 4%~6%w/v of Radix Codonopsis extract.
4. animal compound synergy cefquinome sulfate injection according to claim 2, which is characterized in that further include pharmacy
Upper acceptable auxiliary material, auxiliary material include suspending agent, solubilizer, antioxidant, dispersant, and wherein dispersant includes at least one
Oils dispersant and at least one esters dispersant.
5. animal compound synergy cefquinome sulfate injection according to claim 4, which is characterized in that sulfuric acid cephalo quinoline
Oxime 3%w/v, garlic oil 1%w/v, vitamin E 0.3%w/v, Radix Codonopsis extract 6%w/v, aluminum stearate 2%w/v, sorbester p17
0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, medium chain triglyceride acid esters 30%w/v, injection soybean oil 80%w/v.
6. animal compound synergy cefquinome sulfate injection according to claim 4, which is characterized in that sulfuric acid cephalo quinoline
Oxime 3%w/v, garlic oil 3%w/v, vitamin E 0.3%w/v, Radix Codonopsis extract 5%w/v, aluminum stearate 2%w/v, sorbester p17
0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, medium chain triglyceride acid esters 30%w/v, injection soybean oil 80%w/v.
7. animal compound synergy cefquinome sulfate injection according to claim 4, which is characterized in that sulfuric acid cephalo quinoline
Oxime 3%w/v, garlic oil 5%w/v, vitamin E 0.3%w/v, Radix Codonopsis extract 4%w/v, aluminum stearate 2%w/v, sorbester p17
0.5%w/v, BHA 0.1%w/v, BHT 0.2%w/v, nutmeg isopropyl ester 40%w/v, injection soybean oil 50%w/v.
8. a kind of preparation method of animal compound synergy cefquinome sulfate injection, which is characterized in that include the following steps：
(1), dissolving suspending agent is reheated after keeping the temperature oils dispersant agitating and heating after 40~60 DEG C of cooling, is cooled to 80 DEG C
Antioxidant is added；
(2), continue to cool down, homogenization is spare after Cefquinome sulfate, solubilizer is added；
(3), it after stirring evenly esters dispersant and remaining active constituent, is added to Cefquinome sulfate, the homogeneous of solubilizer
It is uniformly mixed in mixture to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810560815.3A CN108578553A (en) | 2018-05-25 | 2018-05-25 | A kind of animal compound synergy cefquinome sulfate injection and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810560815.3A CN108578553A (en) | 2018-05-25 | 2018-05-25 | A kind of animal compound synergy cefquinome sulfate injection and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108578553A true CN108578553A (en) | 2018-09-28 |
Family
ID=63630494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810560815.3A Pending CN108578553A (en) | 2018-05-25 | 2018-05-25 | A kind of animal compound synergy cefquinome sulfate injection and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108578553A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417559A (en) * | 2012-05-15 | 2013-12-04 | 北京中农大动物保健品技术研究院 | Veterinary compound suspension injection containing ivermectin and praziquantel and preparation method thereof |
| CN104758245A (en) * | 2015-03-10 | 2015-07-08 | 河南牧翔动物药业有限公司 | A cefquinome sulfate oily suspension injection and a preparing method thereof |
| CN106344509A (en) * | 2016-10-26 | 2017-01-25 | 成都乾坤动物药业股份有限公司 | Cefquinome sulfate oil suspension and preparation method thereof |
| CN107157927A (en) * | 2017-05-31 | 2017-09-15 | 合肥中龙神力动物药业有限公司 | Animal cefquinome sulfate injection and preparation method thereof |
-
2018
- 2018-05-25 CN CN201810560815.3A patent/CN108578553A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417559A (en) * | 2012-05-15 | 2013-12-04 | 北京中农大动物保健品技术研究院 | Veterinary compound suspension injection containing ivermectin and praziquantel and preparation method thereof |
| CN104758245A (en) * | 2015-03-10 | 2015-07-08 | 河南牧翔动物药业有限公司 | A cefquinome sulfate oily suspension injection and a preparing method thereof |
| CN106344509A (en) * | 2016-10-26 | 2017-01-25 | 成都乾坤动物药业股份有限公司 | Cefquinome sulfate oil suspension and preparation method thereof |
| CN107157927A (en) * | 2017-05-31 | 2017-09-15 | 合肥中龙神力动物药业有限公司 | Animal cefquinome sulfate injection and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李晔等: "大蒜素与不同抗菌药物联用对耐甲氧西林金黄色葡萄球菌的体外抗菌活性研究 ", 《中华医院感染学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI232111B (en) | Intravaginal clindamycin ovule composition | |
| US6423338B1 (en) | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use | |
| McVay Jr et al. | A study of moniliasis in aureomycin therapy | |
| CN106727436A (en) | A kind of Tilmicosin slow-releasing microcapsule preparation containing plants essential oil and preparation method thereof | |
| CN112972379B (en) | Gamitmycin emulsion, preparation method and application thereof in prevention and treatment of porcine ileitis | |
| EP0337231A2 (en) | I. M. injection forms of gyrase-inhibitors | |
| CN102228462B (en) | Method for preparing veterinary oxytetracycline-artemisinin injection and clinical application of veterinary oxytetracycline-artemisinin injection | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN111789817A (en) | Bromhexine hydrochloride soluble powder for livestock and poultry as well as preparation method and application thereof | |
| CN104800167A (en) | Florfenicol soluble powder and preparation method thereof | |
| CN101829082A (en) | Method for preparing veterinary injection of spectinomycin hydrochloride and lincomycin hydrochloride | |
| CN110327294A (en) | Compound long-acting injection and preparation method thereof containing Enrofloxacin and Flunixin | |
| CN108578553A (en) | A kind of animal compound synergy cefquinome sulfate injection and preparation method | |
| CN105616485A (en) | Doxycycline hydrochloride and origanum oil composition | |
| CN110101837A (en) | A kind of veterinary composition and its liquid preparation and preparation method | |
| CN104800229B (en) | A kind of compound sulfadiazine suspension and preparation method thereof | |
| CN105963688A (en) | Powder for curing intestinal diseases of piglet and enhancing immunity and preparation method thereof | |
| CN107412170B (en) | Cefalonium nanosuspension freeze-dried powder and preparation method thereof | |
| CN104906039B (en) | A kind of Tilmicosin suspension and preparation method thereof | |
| CN112022809A (en) | Oxytetracycline aerosol and preparation method thereof | |
| CN104161761A (en) | Compound terramycin injection and preparation method thereof | |
| JPH01305035A (en) | Veterinary synergistic drug and production thereof | |
| CN105796498B (en) | A kind of powder coating folic acid and preparation method thereof | |
| CN111956612A (en) | Oxytetracycline spray and preparation method thereof | |
| CN110115756A (en) | A kind of Essence with antibacterial, anti-acne effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180928 |
|
| RJ01 | Rejection of invention patent application after publication |